2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1295

Effectiveness and Tolerability of Subcutaneous Tocilizumab in Rheumatoid Arthritis Patients Switched From Intravenous Tocilizumab: Results From the Extension Period of the Musashi Study
Abstract Number: 452

Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose
Abstract Number: 2056

Effectiveness of a Focused Educational Intervention in Improving the Supplementation of Vitamin D Deficiency and Insufficiency
Abstract Number: 297

Effectiveness of Intravenous Cyclophosphamide in Severe or Refractory Juvenile Dermatomyositis – A National Cohort Study: UK and Ireland
Abstract Number: 141

Effectiveness of Prophylaxis with Anti-Gout Medications On Risk of Gout Attacks
Abstract Number: 1156

Effectivity of Methotrexate in Therapy of Juvenile Idiopathic Enthesitis-Related Arthritis
Abstract Number: 2141

Effects of Cigarette Smoking On EARLY Arthritis (CONAART)
Abstract Number: 1323

Effects of Dose Escalation of Tocilizumab in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: Sub-Analysis of a 24-Week Study in a United States Population
Abstract Number: 440

Effects of Fetal Microchimerisms On Disease Onset and Severity in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Abstract Number: 2408

Effects of Ground and Joint Reaction Force Exercise On Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials
Abstract Number: 2434

Effects of Interventions That Aim to Increase Exercise Adherence in People with Arthritis: A Best Evidence Synthesis
Abstract Number: 656

Effects of Nelfinavir On Anti-dsDna Antibody Binding and Pro-Inflammatory Cytokine Gene Expression
Abstract Number: 294

Effects of Obesity On Health-Related Quality of Life in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 727

Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
Abstract Number: 1991

Effects of Odanacatib On the Distal Radius and Tibia in Postmenopausal Women: Improvements in Cortical Geometry and Estimated Bone Strength

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].